These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33248863)

  • 1. Telehealth sustains patient engagement in OUD treatment during COVID-19.
    Langabeer JR; Yatsco A; Champagne-Langabeer T
    J Subst Abuse Treat; 2021 Mar; 122():108215. PubMed ID: 33248863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19.
    Hughto JMW; Peterson L; Perry NS; Donoyan A; Mimiaga MJ; Nelson KM; Pantalone DW
    J Subst Abuse Treat; 2021 Jan; 120():108163. PubMed ID: 33298301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
    Hailu R; Mehrotra A; Huskamp HA; Busch AB; Barnett ML
    JAMA Netw Open; 2023 Jan; 6(1):e2252381. PubMed ID: 36692880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic.
    Castillo M; Conte B; Hinkes S; Mathew M; Na CJ; Norindr A; Serota DP; Forrest DW; Deshpande AR; Bartholomew TS; Tookes HE
    Harm Reduct J; 2020 Nov; 17(1):88. PubMed ID: 33203460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
    J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
    Lin LA; Zhang L; Kim HM; Frost MC
    Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
    Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
    BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
    Yeo EJ; Kralles H; Sternberg D; McCullough D; Nadanasabesan A; Mayo R; Akselrod H; Catalanotti J
    Harm Reduct J; 2021 Dec; 18(1):127. PubMed ID: 34886850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond.
    Pessar SC; Boustead A; Ge Y; Smart R; Pacula RL
    JAMA Health Forum; 2021 Nov; 2(11):e213833. PubMed ID: 35647581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19.
    Lockard R; Priest KC; Gregg J; Buchheit BM
    Subst Abus; 2022; 43(1):1150-1157. PubMed ID: 35499402
    [No Abstract]   [Full Text] [Related]  

  • 14. Telemedicine for contraceptive counseling: Patient experiences during the early phase of the COVID-19 pandemic in New York City.
    Stifani BM; Smith A; Avila K; Boos EW; Ng J; Levi EE; Benfield NC
    Contraception; 2021 Sep; 104(3):254-261. PubMed ID: 33861981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.
    Livingston NA; Ameral V; Banducci AN; Weisberg RB
    J Subst Abuse Treat; 2021 Mar; 122():108222. PubMed ID: 33303255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
    Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where Virtual Care Was Already a Reality: Experiences of a Nationwide Telehealth Service Provider During the COVID-19 Pandemic.
    Uscher-Pines L; Thompson J; Taylor P; Dean K; Yuan T; Tong I; Mehrotra A
    J Med Internet Res; 2020 Dec; 22(12):e22727. PubMed ID: 33112761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
    J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining and supporting high-quality telehealth for patients with opioid use disorder: The promise and potential pitfalls of telehealth expansion.
    Frank CJ; Lin LA
    Subst Abus; 2022; 43(1):1370-1373. PubMed ID: 36222798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.